RTI to study DTC ad response for FDA

Under a $4-million contract from FDA, RTI International researchers will look at consumers' responses to risk, benefit and cost information in direct-to-consumer prescription drug ads. The studies will include:

• Attentional effects in pharma ad viewing—Eye-tracking technology will be used to better understand consumer attention to risks and benefit information.

• Caregiver influence on consumer perceptions of ads—Individuals who have had a disease and their spouses or partners will react to ads for a drug to treat it.

• Cost comparison effect—RTI will assess how prescription drug TV ads with cost comparison information may affect understanding of differences in safety, efficacy and side effects.

• TV ad frequency's effect on perceptions—Researchers will explore how the frequency of exposure affects consumers' understanding of a drug's risks and benefits.

• Web and mobile technology promotion content analysis—Researchers will conduct content analyses of DTC prescription drug ads.

You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.